DrugId:  1
1. Name:  Serrapeptase
2. Groups:  Investigational
3. Description:  Serrapeptase is a proteolytic enzyme preparation used concomitantly with an antibiotic in osteoarticular infections. Serratiopeptidase is under investigation in clinical trial NCT02493179 (Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery).
4. Indication:  Not Available
DrugId:  2
1. Name:  Lanimostim
2. Groups:  Investigational
3. Description:  Not Available
4. Indication:  Investigated for use/treatment in fungal infections.
DrugId:  3
1. Name:  PAC-113
2. Groups:  Investigational
3. Description:  PAC-113 an anti-fungal, for the treatment of oral candidiasis infections. It is a 12 amino-acid antimicrobial peptide derived from a naturally occurring histatin protein found in saliva. In vitro studies demonstrate that it has potent anti-fungal activity against the Candida albicans, including drug-resistant HIV patient isolates. PAC-113 is targeting oral Candida infections in immunocompromised patients and patients with salivary dysfunction.
4. Indication:  Investigated for use/treatment in candidiasis, fungal infections, and saliva and salivary gland dysfunction.
DrugId:  4
1. Name:  Pentamidine
2. Groups:  Approved, Investigational
3. Description:  Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [PubChem]
4. Indication:  For the treatment of pneumonia due to Pneumocystis carinii.
DrugId:  5
1. Name:  Flucytosine
2. Groups:  Approved, Investigational
3. Description:  A fluorinated cytosine analog that is used as an antifungal agent. [PubChem]
4. Indication:  For the treatment (in combination with amphotericin B) of serious infections caused by susceptible strains of Candida (septicemia, endocarditis and urinary system infections) and/or Cryptococcus (meningitis and pulmonary infections).
DrugId:  6
1. Name:  Drotebanol
2. Groups:  Experimental, Illicit
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  7
1. Name:  Flurothyl
2. Groups:  Withdrawn
3. Description:  Flurothyl is a convulsant primarily used in experimental animals. It was formerly used to induce convulsions as a alternative to electroshock therapy.
4. Indication:  Not Available
DrugId:  8
1. Name:  Sertaconazole
2. Groups:  Approved, Investigational
3. Description:  Sertaconazole nitrate is an antifungal medication of the imidazole class. It is available as a cream to treat skin infections such as athlete's foot. [Wikipedia]
4. Indication:  For the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
DrugId:  9
1. Name:  Ethyl chloride
2. Groups:  Approved, Experimental, Investigational
3. Description:  Ethyl chloride, or chloroethane, has a chemical formula C2H5Cl. It was commonly used in the production of tetraethyllead (TEL), which is an additive for gasoline. It was also used in other commerical applications as a chemical reagent. It is still used in the treatment of cellulose to make ethylcellulose for commercial products. Ethyl chloride is used as a diagnostic tool to detect a dead tooth with nonviable pulp.
4. Indication:  Not Available
DrugId:  10
1. Name:  Terconazole
2. Groups:  Approved
3. Description:  Terconazole is an anti-fungal medication, primarily used to treat vaginal fungal infections. [Wikipedia]
4. Indication:  For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.
DrugId:  11
1. Name:  SD118
2. Groups:  Investigational
3. Description:  SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.
4. Indication:  Central Nervous System - Neuropathic pain 
DrugId:  12
1. Name:  Norflurane
2. Groups:  Approved, Investigational
3. Description:  Norflurane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).
4. Indication:  Not Available
DrugId:  13
1. Name:  CHGN111
2. Groups:  Investigational
3. Description:  CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase. Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative stress. It was under investigation until approximately 2007.
4. Indication:  Investigated for use/treatment in skin infections/disorders.
DrugId:  14
1. Name:  Cyclopropane
2. Groups:  Experimental
3. Description:  Cyclopropane was initially investigated because it was thought to be the toxic element in ethylene. Instead, it turned out to be an excellent anesthetic with very rapid onset and recovery while maintaining stable hemodynamics. Its use was ultimately limited because it was highly explosive.
4. Indication:  Not Available
DrugId:  15
1. Name:  DPDPE
2. Groups:  Experimental
3. Description:  A heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
4. Indication:  Not Available
DrugId:  16
1. Name:  Normethadone
2. Groups:  Approved, Illicit
3. Description:  Normethadone is used as an opioid antitussive in combination with Oxilofrine. It is marketed in Canada by Valeant under the tradename Cophylac.
4. Indication:  For use in the treatment of cough when other less potent treatments have failed [FDA Label].
DrugId:  17
1. Name:  Alphacetylmethadol
2. Groups:  Experimental, Illicit
3. Description:  A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. [PubChem]
4. Indication:  Not Available
DrugId:  18
1. Name:  Alphaprodine
2. Groups:  Illicit
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  19
1. Name:  Valpromide
2. Groups:  Experimental
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  20
1. Name:  Barbital
2. Groups:  Illicit
3. Description:  A long-acting barbiturate that depresses most metabolic processes at high doses. It is used as a hypnotic and sedative and may induce dependence. Barbital is also used in veterinary practice for central nervous system depression. Barbital is a schedule IV controlled drug. 
4. Indication:  Not Available
DrugId:  21
1. Name:  Andrographolide
2. Groups:  Investigational
3. Description:  HMPL-004 is a botanical product extracted from a herb that occurs naturally in China. The herb has an extensive history of use in TCM for the treatment of upper respiratory tract infections and other inflammatory and infectious diseases.
4. Indication:  Investigated for use/treatment in ulcerative colitis.
DrugId:  22
1. Name:  Nefopam
2. Groups:  Approved, Investigational
3. Description:  Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.
4. Indication:  Not Available
DrugId:  23
1. Name:  (1R,2S)-2-Phenylcyclopropanaminium
2. Groups:  Experimental
3. Description:  A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
4. Indication:  Not Available
DrugId:  24
1. Name:  Felbinac
2. Groups:  Experimental
3. Description:  Not Available
4. Indication:  Not Available
DrugId:  25
1. Name:  Ziconotide
2. Groups:  Approved
3. Description:  Ziconotide (SNX-111; Prialt) is an atypical analgesic agent for the amelioration of severe and chronic pain. Derived from Conus magus (Cone Snail), it is the synthetic form of an Ï‰-conotoxin peptide. In December 2004 the Food and Drug Administration approved ziconotide when delivered as an infusion into the cerebrospinal fluid using an intrathecal pump system.
4. Indication:  Not Available
